Review





Similar Products

97
MedChemExpress anti human pd 1 antibody
Anti Human Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/PD-1+Antibody/pm42982193-271-20-23
Average 97 stars, based on 1 article reviews
anti human pd 1 antibody - by Bioz Stars, 2026-11
97/100 stars
  Buy from Supplier

99
Bio X Cell anti mouse pd 1
Anti Mouse Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/InVivoMAb+anti-mouse+PD-1/pm42977769-827-155-157
Average 99 stars, based on 1 article reviews
anti mouse pd 1 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

98
Proteintech pd l1
OTUD1 expression correlates with TME regulation and <t>PD‐L1</t> expression in KIRC. (A) Immunoscore heatmap of immune cell scores with high and low OTUD1 expression in KIRC tumors and (B) percentage abundance of infiltrating immune cells for each sample. (C) The correlation of OTUD1 expression and the immune subtypes of KIRC patients from the TISIDB database, including C1 (wound healing), C2 (IFN‐g dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF‐β dominant). (D) The correlation of subgroups with high and low OTUD1 expression and immune checkpoint gene expression. The statistical difference between the two groups was compared using the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05.
Pd L1, supplied by Proteintech, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/PD-L1%2FCD274+Antibody/pmc13744645-249-51-66
Average 98 stars, based on 1 article reviews
pd l1 - by Bioz Stars, 2026-11
98/100 stars
  Buy from Supplier

96
Bio X Cell ɑpd 1
OTUD1 expression correlates with TME regulation and <t>PD‐L1</t> expression in KIRC. (A) Immunoscore heatmap of immune cell scores with high and low OTUD1 expression in KIRC tumors and (B) percentage abundance of infiltrating immune cells for each sample. (C) The correlation of OTUD1 expression and the immune subtypes of KIRC patients from the TISIDB database, including C1 (wound healing), C2 (IFN‐g dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF‐β dominant). (D) The correlation of subgroups with high and low OTUD1 expression and immune checkpoint gene expression. The statistical difference between the two groups was compared using the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05.
ɑpd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/InVivoMAb+anti-mouse+PD-1/pm42982509-279-10-14
Average 96 stars, based on 1 article reviews
ɑpd 1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
MedChemExpress anti mouse pd 1 antibody
OTUD1 expression correlates with TME regulation and <t>PD‐L1</t> expression in KIRC. (A) Immunoscore heatmap of immune cell scores with high and low OTUD1 expression in KIRC tumors and (B) percentage abundance of infiltrating immune cells for each sample. (C) The correlation of OTUD1 expression and the immune subtypes of KIRC patients from the TISIDB database, including C1 (wound healing), C2 (IFN‐g dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF‐β dominant). (D) The correlation of subgroups with high and low OTUD1 expression and immune checkpoint gene expression. The statistical difference between the two groups was compared using the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05.
Anti Mouse Pd 1 Antibody, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/Anti-Mouse+PD-1+Antibody/pm42982193-268-24-27
Average 95 stars, based on 1 article reviews
anti mouse pd 1 antibody - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
Bio X Cell anti pd 1
OTUD1 expression correlates with TME regulation and <t>PD‐L1</t> expression in KIRC. (A) Immunoscore heatmap of immune cell scores with high and low OTUD1 expression in KIRC tumors and (B) percentage abundance of infiltrating immune cells for each sample. (C) The correlation of OTUD1 expression and the immune subtypes of KIRC patients from the TISIDB database, including C1 (wound healing), C2 (IFN‐g dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF‐β dominant). (D) The correlation of subgroups with high and low OTUD1 expression and immune checkpoint gene expression. The statistical difference between the two groups was compared using the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05.
Anti Pd 1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/InVivoMAb+anti-mouse+PD-1/10__1172_slash_jci203453-242-18-21
Average 96 stars, based on 1 article reviews
anti pd 1 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Bio X Cell anti pd 1 clone rpm1 14
( A ) Experimental scheme for (B-F): C57BL/6 mice were vaccinated with ChAdOx1/MVA vaccines encoding SB28 TAAs or DPY one month apart, then challenged intracranially with 500 SB28 tumor cells. Mice received 5x10 8 IU ChAdOx1 I.M. and 1x10 7 PFU MVA I.V. All mice receiving SB28 TAA vaccines also <t>received</t> <t>anti-PD-1</t> and anti-CTLA-4 (ICB; 100 μg each / dose) on days 4, 7, 11, and 14 post-tumor implantation, DPY-vaccinated mice received 200 μg of isotype control. Blood was sampled 14 days post-prime and 12 days post-boost. ( B ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant pool of minimal epitope peptides ( circles ) or without stimulation (DMSO, diamonds ) 2 weeks post-boost ( n = 16, pooled from 2 experiments). ( C ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant peptide pool two weeks post-prime ( squares ) or two weeks post-boost ( circles ) ( n = 16, pooled from 2 experiments). For (B-C), bars depict mean ± SEM, and statistical significance was calculated using 2-way ANOVA with Tukey’s multiple comparisons, with statistically significant comparisons between vaccination conditions shown only between DPY/TAAs and Gpr149/other TAAs for clarity. ( D ) Polyfunctionality of cytokine-expressing CD8 + for each vaccination condition post-boost. ( E ) Intracranial IVIS signal for individual mice at D20 or D21. Data are presented as geometric mean ± geometric SD; statistics calculated using a Kruskal-Wallis test with Dunn’s multiple comparisons. ( F ) Survival of prophylactically vaccinated mice; statistics calculated using a log-rank test. All data pooled from 2 independent experiments ( n = 15-16 mice/group).
Anti Pd 1 Clone Rpm1 14, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/InVivoMAb+anti-mouse+PD-1/bio_rxiv__64898__2026__10__29__760792-248-5-4
Average 96 stars, based on 1 article reviews
anti pd 1 clone rpm1 14 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

95
MedChemExpress anti 169 mouse pd 1
( A ) Experimental scheme for (B-F): C57BL/6 mice were vaccinated with ChAdOx1/MVA vaccines encoding SB28 TAAs or DPY one month apart, then challenged intracranially with 500 SB28 tumor cells. Mice received 5x10 8 IU ChAdOx1 I.M. and 1x10 7 PFU MVA I.V. All mice receiving SB28 TAA vaccines also <t>received</t> <t>anti-PD-1</t> and anti-CTLA-4 (ICB; 100 μg each / dose) on days 4, 7, 11, and 14 post-tumor implantation, DPY-vaccinated mice received 200 μg of isotype control. Blood was sampled 14 days post-prime and 12 days post-boost. ( B ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant pool of minimal epitope peptides ( circles ) or without stimulation (DMSO, diamonds ) 2 weeks post-boost ( n = 16, pooled from 2 experiments). ( C ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant peptide pool two weeks post-prime ( squares ) or two weeks post-boost ( circles ) ( n = 16, pooled from 2 experiments). For (B-C), bars depict mean ± SEM, and statistical significance was calculated using 2-way ANOVA with Tukey’s multiple comparisons, with statistically significant comparisons between vaccination conditions shown only between DPY/TAAs and Gpr149/other TAAs for clarity. ( D ) Polyfunctionality of cytokine-expressing CD8 + for each vaccination condition post-boost. ( E ) Intracranial IVIS signal for individual mice at D20 or D21. Data are presented as geometric mean ± geometric SD; statistics calculated using a Kruskal-Wallis test with Dunn’s multiple comparisons. ( F ) Survival of prophylactically vaccinated mice; statistics calculated using a log-rank test. All data pooled from 2 independent experiments ( n = 15-16 mice/group).
Anti 169 Mouse Pd 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/Anti-Mouse+PD-1+Antibody/10__1158_slash_1535___7163__mct___26___0461-51-4-8
Average 95 stars, based on 1 article reviews
anti 169 mouse pd 1 - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

93
InvivoGen anti mouse pd l1 antibody
( A ) Experimental scheme for (B-F): C57BL/6 mice were vaccinated with ChAdOx1/MVA vaccines encoding SB28 TAAs or DPY one month apart, then challenged intracranially with 500 SB28 tumor cells. Mice received 5x10 8 IU ChAdOx1 I.M. and 1x10 7 PFU MVA I.V. All mice receiving SB28 TAA vaccines also <t>received</t> <t>anti-PD-1</t> and anti-CTLA-4 (ICB; 100 μg each / dose) on days 4, 7, 11, and 14 post-tumor implantation, DPY-vaccinated mice received 200 μg of isotype control. Blood was sampled 14 days post-prime and 12 days post-boost. ( B ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant pool of minimal epitope peptides ( circles ) or without stimulation (DMSO, diamonds ) 2 weeks post-boost ( n = 16, pooled from 2 experiments). ( C ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant peptide pool two weeks post-prime ( squares ) or two weeks post-boost ( circles ) ( n = 16, pooled from 2 experiments). For (B-C), bars depict mean ± SEM, and statistical significance was calculated using 2-way ANOVA with Tukey’s multiple comparisons, with statistically significant comparisons between vaccination conditions shown only between DPY/TAAs and Gpr149/other TAAs for clarity. ( D ) Polyfunctionality of cytokine-expressing CD8 + for each vaccination condition post-boost. ( E ) Intracranial IVIS signal for individual mice at D20 or D21. Data are presented as geometric mean ± geometric SD; statistics calculated using a Kruskal-Wallis test with Dunn’s multiple comparisons. ( F ) Survival of prophylactically vaccinated mice; statistics calculated using a log-rank test. All data pooled from 2 independent experiments ( n = 15-16 mice/group).
Anti Mouse Pd L1 Antibody, supplied by InvivoGen, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+pd+1+antibody/Anti-mPD-L1-mIgG1e3/pmc13762663-354-4-7
Average 93 stars, based on 1 article reviews
anti mouse pd l1 antibody - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

Image Search Results


OTUD1 expression correlates with TME regulation and PD‐L1 expression in KIRC. (A) Immunoscore heatmap of immune cell scores with high and low OTUD1 expression in KIRC tumors and (B) percentage abundance of infiltrating immune cells for each sample. (C) The correlation of OTUD1 expression and the immune subtypes of KIRC patients from the TISIDB database, including C1 (wound healing), C2 (IFN‐g dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF‐β dominant). (D) The correlation of subgroups with high and low OTUD1 expression and immune checkpoint gene expression. The statistical difference between the two groups was compared using the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05.

Journal: MedComm

Article Title: OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

doi: 10.1002/mco2.71144

Figure Lengend Snippet: OTUD1 expression correlates with TME regulation and PD‐L1 expression in KIRC. (A) Immunoscore heatmap of immune cell scores with high and low OTUD1 expression in KIRC tumors and (B) percentage abundance of infiltrating immune cells for each sample. (C) The correlation of OTUD1 expression and the immune subtypes of KIRC patients from the TISIDB database, including C1 (wound healing), C2 (IFN‐g dominant), C3 (inflammatory), C4 (lymphocyte depleted), C5 (immunologically quiet), and C6 (TGF‐β dominant). (D) The correlation of subgroups with high and low OTUD1 expression and immune checkpoint gene expression. The statistical difference between the two groups was compared using the Wilcox test. * p < 0.05, ** p < 0.01, *** p < 0.001, ns p > 0.05.

Article Snippet: After 48 h of transfection, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, followed by permeabilization with 0.5% Triton X‐100 for 10 min. After three washes with PBS, nonspecific binding was blocked by incubation with 5% goat serum at room temperature for 1 h. For LAMP1 and PD‐L1 co‐localization analysis, cells were incubated overnight at 4°C with primary antibodies against LAMP1 (1:400, Proteintech, Cat: 84658‐5‐RR0) and PD‐L1 (1:400, Proteintech, Cat: 66248‐1‐Ig).

Techniques: Expressing, Immune Cell, Gene Expression, Stem Cell

OTUD1 overexpression induced PD‐L1 reduction in KIRC. (A) OTUD1 and PD‐L1 protein expression were detected by Immunoblot analysis for six pairs of randomly selected KIRC tissues and matched para‐cancerous tissues. (B) The collected tumors from 786‐O bearing mouse modelwere analyzed by immunofluorescence staining using antibodies against PD‐L1 (green) and OTUD1 (red). Representative images from two independent experiments are shown. Nuclei were counterstained with DAPI (blue). 200× magnification, Scale bar = 100 µm. (C) Effects of overexpression or knockdown of OTUD1 on PD‐L1 protein expression in 786‐O cells and Renca cells, as detected by Immunoblot analysis. (D) Fluorescence quantitative analysis of flow cytometry for PD‐L1 distribution on the surface of 786‐O cells and (E) Renca cells. The data are expressed as mean ± SD from three biological replicates. (F) Representative flow cytometry analysis for PD‐L1 on the surface of 786‐O cells and (G) Renca cells with or without co‐culture with supernatant of NK cells. (H) Fluorescence quantitative analysis by flow cytometry for PD‐L1 on the surface of 786‐O cells and (I) Renca cells with or without co‐culture with supernatant of NK cells. The data are expressed as mean ± SD from three biological replicates. Significance was assessed using a two‐tailed paired Student's t ‐test (left panels of D, E), a one‐way ANOVA followed by Dunnett's multiple comparisons test (right panels of D, E; H, I). Data are representative of at least three (A, C) independent experiments with similar results.

Journal: MedComm

Article Title: OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

doi: 10.1002/mco2.71144

Figure Lengend Snippet: OTUD1 overexpression induced PD‐L1 reduction in KIRC. (A) OTUD1 and PD‐L1 protein expression were detected by Immunoblot analysis for six pairs of randomly selected KIRC tissues and matched para‐cancerous tissues. (B) The collected tumors from 786‐O bearing mouse modelwere analyzed by immunofluorescence staining using antibodies against PD‐L1 (green) and OTUD1 (red). Representative images from two independent experiments are shown. Nuclei were counterstained with DAPI (blue). 200× magnification, Scale bar = 100 µm. (C) Effects of overexpression or knockdown of OTUD1 on PD‐L1 protein expression in 786‐O cells and Renca cells, as detected by Immunoblot analysis. (D) Fluorescence quantitative analysis of flow cytometry for PD‐L1 distribution on the surface of 786‐O cells and (E) Renca cells. The data are expressed as mean ± SD from three biological replicates. (F) Representative flow cytometry analysis for PD‐L1 on the surface of 786‐O cells and (G) Renca cells with or without co‐culture with supernatant of NK cells. (H) Fluorescence quantitative analysis by flow cytometry for PD‐L1 on the surface of 786‐O cells and (I) Renca cells with or without co‐culture with supernatant of NK cells. The data are expressed as mean ± SD from three biological replicates. Significance was assessed using a two‐tailed paired Student's t ‐test (left panels of D, E), a one‐way ANOVA followed by Dunnett's multiple comparisons test (right panels of D, E; H, I). Data are representative of at least three (A, C) independent experiments with similar results.

Article Snippet: After 48 h of transfection, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, followed by permeabilization with 0.5% Triton X‐100 for 10 min. After three washes with PBS, nonspecific binding was blocked by incubation with 5% goat serum at room temperature for 1 h. For LAMP1 and PD‐L1 co‐localization analysis, cells were incubated overnight at 4°C with primary antibodies against LAMP1 (1:400, Proteintech, Cat: 84658‐5‐RR0) and PD‐L1 (1:400, Proteintech, Cat: 66248‐1‐Ig).

Techniques: Over Expression, Expressing, Western Blot, Analysis, Immunofluorescence, Staining, Knockdown, Fluorescence, Flow Cytometry, Co-culture Assay, Two Tailed Test

OTUD1‐induced PD‐L1 reduction affects T cell‐dependent cytotoxicity. (A) Schematic representation of the in vitro co‐culture system and subsequent analysis of tumor cells and Jurkat T cells. (B) Representative flow cytometry analysis and (C) statistical graphs of the MFI for CD69 on the surface of T cells, indicating the activation status of the T cells upon co‐culture with tumor cells. The data are expressed as mean ± SD from three biological replicates. (D) Quantitative analysis of the gene expression encoding IFN‐γ and TNF‐α by qRT‐PCR. Relative amount of IFN‐γ and TNF‐α in culture medium by ELISA, following 24 h of Jurkat T cells co‐culture with tumor cells. The data are expressed as mean ± SD from three biological replicates. (E) Representative image of the flow cytometry analysis showed that T cell‐dependent apoptosis occurred in 786‐O cells after co‐culture with Jurkat T cells. (F) The percentages of early apoptotic, late apoptotic, and necrotic cells, as well as live healthy cells, are represented. The data are expressed as mean ± SD from three biological replicates. Significance was assessed using a one‐way ANOVA followed by Tukey's multiple comparisons test (C).

Journal: MedComm

Article Title: OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

doi: 10.1002/mco2.71144

Figure Lengend Snippet: OTUD1‐induced PD‐L1 reduction affects T cell‐dependent cytotoxicity. (A) Schematic representation of the in vitro co‐culture system and subsequent analysis of tumor cells and Jurkat T cells. (B) Representative flow cytometry analysis and (C) statistical graphs of the MFI for CD69 on the surface of T cells, indicating the activation status of the T cells upon co‐culture with tumor cells. The data are expressed as mean ± SD from three biological replicates. (D) Quantitative analysis of the gene expression encoding IFN‐γ and TNF‐α by qRT‐PCR. Relative amount of IFN‐γ and TNF‐α in culture medium by ELISA, following 24 h of Jurkat T cells co‐culture with tumor cells. The data are expressed as mean ± SD from three biological replicates. (E) Representative image of the flow cytometry analysis showed that T cell‐dependent apoptosis occurred in 786‐O cells after co‐culture with Jurkat T cells. (F) The percentages of early apoptotic, late apoptotic, and necrotic cells, as well as live healthy cells, are represented. The data are expressed as mean ± SD from three biological replicates. Significance was assessed using a one‐way ANOVA followed by Tukey's multiple comparisons test (C).

Article Snippet: After 48 h of transfection, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, followed by permeabilization with 0.5% Triton X‐100 for 10 min. After three washes with PBS, nonspecific binding was blocked by incubation with 5% goat serum at room temperature for 1 h. For LAMP1 and PD‐L1 co‐localization analysis, cells were incubated overnight at 4°C with primary antibodies against LAMP1 (1:400, Proteintech, Cat: 84658‐5‐RR0) and PD‐L1 (1:400, Proteintech, Cat: 66248‐1‐Ig).

Techniques: In Vitro, Co-culture Assay, Analysis, Flow Cytometry, Activation Assay, Gene Expression, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Co-Culture, Cell Culture

OTUD1 promotes PD‐L1 degradation through the autophagy‐lysosomal pathway. (A) Cycloheximide (CHX) was used to block protein synthesis. Immunoblots of protein expression levels and (B) quantification of PD‐L1 in 786‐O cells overexpressing OTUD1 and control cells. (C) MG132 was used to block proteasome activity. Immunoblots of the protein expression levels of PD‐L1 in 786‐O cells overexpressing OTUD1 and control cells. (D) Immunoblots and quantification of the autophagy‐associated protein expression levels of p62, LC3‐I, and LC3‐II in 786‐O cells overexpressing OTUD1. (E) Transmission electron microscopy (TEM) showing an increase in autophagosomes and autolysosomes in 786‐O cells with OTUD1 overexpression. Representative images from two independent experiments are shown. Yellow arrow: phagosomes; red arrow: phagolysosomes; scale bar = 10 µm. (F) Representative fluorescent microscopy images from two independent experiments and (G) a heat map showing the fluorescence intensity of DALGreen and DAPRed in 786‐O cells with OTUD1 overexpression are shown. Scale bar = 20 µm. (H) CQ and 3MA were used to block the autophagy‐lysosomal pathway. Immunoblots of the protein expression level of PD‐L1 in 786‐O cells overexpressing OTUD1 and control cells. (I) NAG relative activities of 786‐O cells overexpressing OTUD1 and control cells were measured and presented in histograms. The results are expressed as mean ± SD from three biological replicates. (J) Representative fluorescent microscopy images from two independent experiments are shown. (K) The statistical fluorescence intensity showing the localization of PD‐L1 (green) and LAMP1 (red) in 786‐O cells with OTUD1 overexpression and control cells. Scale bar = 20 µm. Significance was assessed using a two‐way ANOVA followed by Šídák's multiple comparisons test (B) and a two‐tailed paired Student's t ‐test (D, I). Data are representative of at least three (A, C, D, H) independent experiments with similar results.

Journal: MedComm

Article Title: OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

doi: 10.1002/mco2.71144

Figure Lengend Snippet: OTUD1 promotes PD‐L1 degradation through the autophagy‐lysosomal pathway. (A) Cycloheximide (CHX) was used to block protein synthesis. Immunoblots of protein expression levels and (B) quantification of PD‐L1 in 786‐O cells overexpressing OTUD1 and control cells. (C) MG132 was used to block proteasome activity. Immunoblots of the protein expression levels of PD‐L1 in 786‐O cells overexpressing OTUD1 and control cells. (D) Immunoblots and quantification of the autophagy‐associated protein expression levels of p62, LC3‐I, and LC3‐II in 786‐O cells overexpressing OTUD1. (E) Transmission electron microscopy (TEM) showing an increase in autophagosomes and autolysosomes in 786‐O cells with OTUD1 overexpression. Representative images from two independent experiments are shown. Yellow arrow: phagosomes; red arrow: phagolysosomes; scale bar = 10 µm. (F) Representative fluorescent microscopy images from two independent experiments and (G) a heat map showing the fluorescence intensity of DALGreen and DAPRed in 786‐O cells with OTUD1 overexpression are shown. Scale bar = 20 µm. (H) CQ and 3MA were used to block the autophagy‐lysosomal pathway. Immunoblots of the protein expression level of PD‐L1 in 786‐O cells overexpressing OTUD1 and control cells. (I) NAG relative activities of 786‐O cells overexpressing OTUD1 and control cells were measured and presented in histograms. The results are expressed as mean ± SD from three biological replicates. (J) Representative fluorescent microscopy images from two independent experiments are shown. (K) The statistical fluorescence intensity showing the localization of PD‐L1 (green) and LAMP1 (red) in 786‐O cells with OTUD1 overexpression and control cells. Scale bar = 20 µm. Significance was assessed using a two‐way ANOVA followed by Šídák's multiple comparisons test (B) and a two‐tailed paired Student's t ‐test (D, I). Data are representative of at least three (A, C, D, H) independent experiments with similar results.

Article Snippet: After 48 h of transfection, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, followed by permeabilization with 0.5% Triton X‐100 for 10 min. After three washes with PBS, nonspecific binding was blocked by incubation with 5% goat serum at room temperature for 1 h. For LAMP1 and PD‐L1 co‐localization analysis, cells were incubated overnight at 4°C with primary antibodies against LAMP1 (1:400, Proteintech, Cat: 84658‐5‐RR0) and PD‐L1 (1:400, Proteintech, Cat: 66248‐1‐Ig).

Techniques: Blocking Assay, Western Blot, Expressing, Control, Activity Assay, Transmission Assay, Electron Microscopy, Over Expression, Microscopy, Fluorescence, Two Tailed Test

OTUD1 regulates PD‐L1 abundance through the Akt‐mTOR‐TFEB pathway. (A) Transcriptional profiling reveals the key pathways influenced by OTUD1 in 786‐O cells. (B) Immunoblots of the protein expression levels of Akt, p‐Akt, mTOR, p‐mTOR, TFEB, and p‐TFEB in 786‐O cells overexpressing OTUD1 and control cells. (C) MHY1485 was used to activate the mTOR pathway and inhibit autophagy. Immunoblots of the protein expression levels of mTOR, p‐mTOR, P62, LC3B, and PD‐L1 in 786‐O cells with overexpressed OTUD1 expression and control cells. (D) Immunoblots of the protein expression level of cytosolic and nuclear protein accumulation of TFEB in 786‐O cells with overexpressed OTUD1 expression and control cells. (E) Fluorescence microscopy images of TFEB subcellular localization in 786‐O cells with overexpressed OTUD1 expression and control cells. Representative images from two independent experiments are shown. Scale bar = 20 µm. (F) Quantitative analysis of the mRNA expression of TPP1 , MAP1LC3 , LAMP1 , GABARAP , CTSA , and CTSD in 786‐O cells with OTUD1 overexpression and control cells by qRT‐PCR. The results are expressed as mean ± SD from three biological replicates. (G) Molecular docking model of the interactions between OTUD1 and AKT. (H) Co‐immunoprecipitation (Co‐IP) assay was performed to examine the interaction between HA‐OTUD1 and FLAG‐AKT. (I) The effect of AKT ubiquitination by overexpressed OTUD1 was examined in control and OTUD1‐overexpressing 786‐O cells by HA‐Ubiquitin assay. The “vector” group represents cells transfected with the empty plasmid control; the “OE‐OTUD1” group represents cells transfected with the OTUD1‐overexpression plasmid. (J) Schematic working model. OTUD1 binding to AKT decreases mTOR pathway activity, followed by translocation of TFEB to the nucleus, thereby triggering autophagy‐dependent degradation of PD‐L1 in the lysosome. Data are representative of at least three (A, C, D, H, I) independent experiments with similar results.

Journal: MedComm

Article Title: OTUD1 Prevents Immunosuppression via Promoting Lysosomal‐Associated Degradation of PD‐L1

doi: 10.1002/mco2.71144

Figure Lengend Snippet: OTUD1 regulates PD‐L1 abundance through the Akt‐mTOR‐TFEB pathway. (A) Transcriptional profiling reveals the key pathways influenced by OTUD1 in 786‐O cells. (B) Immunoblots of the protein expression levels of Akt, p‐Akt, mTOR, p‐mTOR, TFEB, and p‐TFEB in 786‐O cells overexpressing OTUD1 and control cells. (C) MHY1485 was used to activate the mTOR pathway and inhibit autophagy. Immunoblots of the protein expression levels of mTOR, p‐mTOR, P62, LC3B, and PD‐L1 in 786‐O cells with overexpressed OTUD1 expression and control cells. (D) Immunoblots of the protein expression level of cytosolic and nuclear protein accumulation of TFEB in 786‐O cells with overexpressed OTUD1 expression and control cells. (E) Fluorescence microscopy images of TFEB subcellular localization in 786‐O cells with overexpressed OTUD1 expression and control cells. Representative images from two independent experiments are shown. Scale bar = 20 µm. (F) Quantitative analysis of the mRNA expression of TPP1 , MAP1LC3 , LAMP1 , GABARAP , CTSA , and CTSD in 786‐O cells with OTUD1 overexpression and control cells by qRT‐PCR. The results are expressed as mean ± SD from three biological replicates. (G) Molecular docking model of the interactions between OTUD1 and AKT. (H) Co‐immunoprecipitation (Co‐IP) assay was performed to examine the interaction between HA‐OTUD1 and FLAG‐AKT. (I) The effect of AKT ubiquitination by overexpressed OTUD1 was examined in control and OTUD1‐overexpressing 786‐O cells by HA‐Ubiquitin assay. The “vector” group represents cells transfected with the empty plasmid control; the “OE‐OTUD1” group represents cells transfected with the OTUD1‐overexpression plasmid. (J) Schematic working model. OTUD1 binding to AKT decreases mTOR pathway activity, followed by translocation of TFEB to the nucleus, thereby triggering autophagy‐dependent degradation of PD‐L1 in the lysosome. Data are representative of at least three (A, C, D, H, I) independent experiments with similar results.

Article Snippet: After 48 h of transfection, cells were fixed with 4% paraformaldehyde at room temperature for 15 min, followed by permeabilization with 0.5% Triton X‐100 for 10 min. After three washes with PBS, nonspecific binding was blocked by incubation with 5% goat serum at room temperature for 1 h. For LAMP1 and PD‐L1 co‐localization analysis, cells were incubated overnight at 4°C with primary antibodies against LAMP1 (1:400, Proteintech, Cat: 84658‐5‐RR0) and PD‐L1 (1:400, Proteintech, Cat: 66248‐1‐Ig).

Techniques: Profiling, Western Blot, Expressing, Control, Fluorescence, Microscopy, Analysis, Over Expression, Quantitative RT-PCR, Docking Assay, Co-Immunoprecipitation Assay, Ubiquitin Proteomics, Plasmid Preparation, Transfection, Binding Assay, Activity Assay, Translocation Assay, Significance Assay, Affinity Binding Assay

( A ) Experimental scheme for (B-F): C57BL/6 mice were vaccinated with ChAdOx1/MVA vaccines encoding SB28 TAAs or DPY one month apart, then challenged intracranially with 500 SB28 tumor cells. Mice received 5x10 8 IU ChAdOx1 I.M. and 1x10 7 PFU MVA I.V. All mice receiving SB28 TAA vaccines also received anti-PD-1 and anti-CTLA-4 (ICB; 100 μg each / dose) on days 4, 7, 11, and 14 post-tumor implantation, DPY-vaccinated mice received 200 μg of isotype control. Blood was sampled 14 days post-prime and 12 days post-boost. ( B ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant pool of minimal epitope peptides ( circles ) or without stimulation (DMSO, diamonds ) 2 weeks post-boost ( n = 16, pooled from 2 experiments). ( C ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant peptide pool two weeks post-prime ( squares ) or two weeks post-boost ( circles ) ( n = 16, pooled from 2 experiments). For (B-C), bars depict mean ± SEM, and statistical significance was calculated using 2-way ANOVA with Tukey’s multiple comparisons, with statistically significant comparisons between vaccination conditions shown only between DPY/TAAs and Gpr149/other TAAs for clarity. ( D ) Polyfunctionality of cytokine-expressing CD8 + for each vaccination condition post-boost. ( E ) Intracranial IVIS signal for individual mice at D20 or D21. Data are presented as geometric mean ± geometric SD; statistics calculated using a Kruskal-Wallis test with Dunn’s multiple comparisons. ( F ) Survival of prophylactically vaccinated mice; statistics calculated using a log-rank test. All data pooled from 2 independent experiments ( n = 15-16 mice/group).

Journal: bioRxiv

Article Title: Vaccination targeting the novel endogenous tumor-associated antigen Gpr149 induces protective immunity against checkpoint inhibitor-refractory SB28 glioblastoma

doi: 10.64898/2026.10.29.760792

Figure Lengend Snippet: ( A ) Experimental scheme for (B-F): C57BL/6 mice were vaccinated with ChAdOx1/MVA vaccines encoding SB28 TAAs or DPY one month apart, then challenged intracranially with 500 SB28 tumor cells. Mice received 5x10 8 IU ChAdOx1 I.M. and 1x10 7 PFU MVA I.V. All mice receiving SB28 TAA vaccines also received anti-PD-1 and anti-CTLA-4 (ICB; 100 μg each / dose) on days 4, 7, 11, and 14 post-tumor implantation, DPY-vaccinated mice received 200 μg of isotype control. Blood was sampled 14 days post-prime and 12 days post-boost. ( B ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant pool of minimal epitope peptides ( circles ) or without stimulation (DMSO, diamonds ) 2 weeks post-boost ( n = 16, pooled from 2 experiments). ( C ) Proportion of CD8 + T cells expressing IFN- γ after ex vivo restimulation of PBMCs with the relevant peptide pool two weeks post-prime ( squares ) or two weeks post-boost ( circles ) ( n = 16, pooled from 2 experiments). For (B-C), bars depict mean ± SEM, and statistical significance was calculated using 2-way ANOVA with Tukey’s multiple comparisons, with statistically significant comparisons between vaccination conditions shown only between DPY/TAAs and Gpr149/other TAAs for clarity. ( D ) Polyfunctionality of cytokine-expressing CD8 + for each vaccination condition post-boost. ( E ) Intracranial IVIS signal for individual mice at D20 or D21. Data are presented as geometric mean ± geometric SD; statistics calculated using a Kruskal-Wallis test with Dunn’s multiple comparisons. ( F ) Survival of prophylactically vaccinated mice; statistics calculated using a log-rank test. All data pooled from 2 independent experiments ( n = 15-16 mice/group).

Article Snippet: Antibodies were purchased from BioXcell (anti-PD-1 clone RPM1-14 or 29F.1A12; anti-CTLA-4 clone 9H10).

Techniques: Vaccines, Tumor Implantation, Control, Expressing, Ex Vivo